|
2025
|
Invention
|
Neurodegenerative disorders and muscle diseases implicating pufas.
Some aspects of the invention... |
|
|
Invention
|
Inhibition of cellular dysfunction and cell death with deuterated polyunsaturated fatty acids.
D... |
|
|
Invention
|
Deuterated polyunsaturated fatty acids or esters thereof for cosmetic applications.
Disclosed ar... |
|
|
Invention
|
Pharmaceutical compositions of d10-docosahexaenoic acid or esters thereof.
Disclosed are methods... |
|
2024
|
Invention
|
Site-specific isotopic labeling of 1,4-diene systems.
Methods for preparing isotopically modifie... |
|
|
Invention
|
Methods for treating tauopathy.
Disclosed are uses of isotopically modified polyunsaturated comp... |
|
|
Invention
|
Isotopically modified composition and therapeutic uses thereof.
Isotopically modified polyunsatu... |
|
|
Invention
|
Methods and compositions for treatment of inflammatory disease.
Disclosed herein are composition... |
|
2023
|
Invention
|
Synergistic combination therapy for treating als.
Disclosed are methods for inhibiting the progr... |
|
|
Invention
|
Processes for isotopic modification of polyunsaturated fatty acids and derivatives thereof.
Disc... |
|
|
Invention
|
Prophylactic methods for treating als.
Amyotrophic lateral sclerosis (ALS) is a debilitating and... |
|
|
Invention
|
Pharmaceutical compositions of d10-docosahexaenoic acid or esters thereof. Disclosed are methods ... |
|
|
Invention
|
Disorders implicating pufa oxidation. Some aspects of the invention provide for a method of treat... |
|
|
Invention
|
Methods for monitoring patient response to treatment of retinal oxidative diseases.
Disclosed ar... |
|
2022
|
Invention
|
Anti-inflammatory methods with compositions comprising site-specific isotopically-modified fatty ... |
|
|
Invention
|
Methods and compositions for treatment of inflammatory disease. Disclosed herein are compositions... |
|
|
Invention
|
Methods for inhibiting the progression of neurodegenerative diseases.
Disclosed are methods for ... |
|
|
Invention
|
Methods of treating amyotrophic lateral sclerosis.
Disclosed are methods for inhibiting the prog... |
|
|
Invention
|
Methods, systems and compositions for inhibition of cellular dysfunction and cell death with deut... |
|
|
Invention
|
Site-specific isotopic labeling of 1,4-diene systems. Methods for preparing isotopically modified... |
|
|
Invention
|
Methods for inhibiting the progression of oxidative retinal disease.
Disclosed are methods for i... |
|
|
Invention
|
Oxidative retinal diseases.
Some aspects of the invention provide for a method of treating Wet a... |
|
|
Invention
|
Synergistic combination therapy for treating als. Disclosed are methods for inhibiting the progre... |
|
2021
|
Invention
|
Isotopically modified components and therapeutic uses thereof.
Methods are provided of identifyi... |
|
|
Invention
|
Methods of treating amyotrophic lateral sclerosis. Disclosed are methods for inhibiting the progr... |
|
|
Invention
|
Processes for isotopic modification of polyunsaturated fatty acids and derivatives thereof. Discl... |
|
2020
|
Invention
|
Alleviating oxidative stress disorders with pufa derivatives. Some aspects of the invention provi... |
|
2019
|
Invention
|
Deuterated compounds, compositions, and methods of use.
Deuterated polyunsaturated fatty acid (“... |
|
|
Invention
|
Stabilized polyunsaturated compounds and uses thereof.
Methods are provided for treating a subje... |
|
2018
|
Invention
|
Disorders implicating pufa oxidation.
Some aspects of the invention provide for a method of trea... |
|
|
Invention
|
Neurodegenerative disorders and muscle diseases implicating pufas. Some aspects of the invention ... |
|
|
Invention
|
Oxidative retinal diseases. Some aspects of the invention provide for a method of treating Wet an... |
|
|
Invention
|
Impaired energy processing disorders and mitochondrial deficiency.
Some aspects of the invention... |
|
2017
|
Invention
|
Isotopically modified components and therapeutic uses thereof. Methods are provided of identifyin... |
